Indeed, it has been shown that the anti-CD38 mAb Daratumumab enhances effectors cell-mediated lysis, degranulation, and ADCC against CD38+ tumor cells [84,85,86,87] improving the overall response rate in MM patients [88,89,90,91]. Here, CD38 is linked to Miyoshi myopathy.